GLUE

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. (GLUE) has 12 SEC Form 4 filings (28 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 16, 2026.

The most active filer is Chief Operating Officer Champoux Jennifer with 4 filings. Insiders have net sold $1.9M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Markus Warmuth
  • Employees:142
  • HQ:Boston, MA, US
  • IPO:2021-06-24

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.9M

reported sales (SEC code S)

Unique Insiders

4

in the rolling window

Market Cap

$2.0B

latest known value

Source
Sale$102KJul 16SEC ↗
Sale$140KJul 7SEC ↗
Sale$132KJul 1SEC ↗
Sale$138KJun 30SEC ↗
Manning Anthony M.First filing
Sale$231KJun 30SEC ↗
Janku FilipFirst filing
Sale$240KJun 25SEC ↗
Janku FilipFirst filing
Sale$643KJun 25SEC ↗
Sale$60KJun 25SEC ↗
Sale$44KJun 25SEC ↗
Townson SharonFirst filing
Sale$57KJun 18SEC ↗
Sale$41KJun 18SEC ↗
Champoux JenniferFirst filing
Sale$44KMay 28SEC ↗

Related companies

Monte Rosa Therapeutics, Inc. is in the Healthcare sector.